Daniel M Rotroff

List of Publications by Year
in descending order

67 papers	4,983 citations	186254 28 h-index	98792 67 g-index
73 all docs	73 docs citations	73 times ranked	6503 citing authors

#	Article	IF	Citations
1	In Vitro Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project. Environmental Health Perspectives, 2010, 118, 485-492.	6.0	519
2	Update on EPAâ€™s ToxCast Program: Providing High Throughput Decision Support Tools for Chemical Risk Management. Chemical Research in Toxicology, 2012, 25, 1287-1302.	3.3	410
3	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€"An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.8	396
4	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.8	362
5	Integration of Dosimetry, Exposure, and High-Throughput Screening Data in Chemical Toxicity Assessment. Toxicological Sciences, 2012, 125, 157-174.	3.1	336
6	Integrated Model of Chemical Perturbations of a Biological Pathway Using 18In VitroHigh-Throughput Screening Assays for the Estrogen Receptor. Toxicological Sciences, 2015, 148, 137-154.	3.1	251
7	Incorporating Human Dosimetry and Exposure into High-ThroughputIn VitroToxicity Screening. Toxicological Sciences, 2010, 117, 348-358.	3.1	222
8	Impact of Environmental Chemicals on Key Transcription Regulators and Correlation to Toxicity End Points within EPAâ€™s ToxCast Program. Chemical Research in Toxicology, 2010, 23, 578-590.	3.3	190
9	Editor's Highlight: Analysis of the Effects of Cell Stress and Cytotoxicity onIn VitroAssay Activity Across a Diverse Chemical and Assay Space. Toxicological Sciences, 2016, 152, 323-339.	3.1	171
10	Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway. Scientific Reports, 2014, 4, 5664.	3.3	167
11	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	21.4	165
12	Analysis of Eight Oil Spill Dispersants Using Rapid, In Vitro Tests for Endocrine and Other Biological Activity. Environmental Science & Technology, 2010, 44, 5979-5985.	10.0	162
13	Using in Vitro High Throughput Screening Assays to Identify Potential Endocrine-Disrupting Chemicals. Environmental Health Perspectives, 2013, 121, 7-14.	6.0	134
14	Profiling the Reproductive Toxicity of Chemicals from Multigeneration Studies in the Toxicity Reference Database. Toxicological Sciences, 2009, 110, 181-190.	3.1	120
15	Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Translational Psychiatry, 2016, 6, e894-e894.	4.8	81
16	Predictive Endocrine Testing in the 21st Century Using in Vitro Assays of Estrogen Receptor Signaling Responses. Environmental Science & Technology, 2014, 48, 8706-8716.	10.0	71
17	Development of a Thyroperoxidase Inhibition Assay for High-Throughput Screening. Chemical Research in Toxicology, 2014, 27, 387-399.	3.3	70
18	Gene set analysis methods: a systematic comparison. BioData Mining, 2018, 11, 8.	4.0	68

#	Article	IF	Citations
19	Binary Classification of a Large Collection of Environmental Chemicals from Estrogen Receptor Assays by Quantitative Structureâ€“Activity Relationship and Machine Learning Methods. Journal of Chemical Information and Modeling, 2013, 53, 3244-3261.	5.4	66
20	Maternal smoking impacts key biological pathways in newborns through epigenetic modification in Utero. BMC Genomics, 2016, 17, 976.	2.8	56
21	Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma. Chromosome Research, 2014, 22, 305-319.	2.2	54
22	Xenobiotic-Metabolizing Enzyme and Transporter Gene Expression in Primary Cultures of Human Hepatocytes Modulated by Toxcast Chemicals. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2010, 13, 329-346.	6.5	53
23	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific Data, 2017, 4, 170140.	5.3	49
24	Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease. Liver International, 2020, 40, 1178-1188.	3.9	45
25	Real-Time Growth Kinetics Measuring Hormone Mimicry for ToxCast Chemicals in T-47D Human Ductal Carcinoma Cells. Chemical Research in Toxicology, 2013, 26, 1097-1107.	3.3	41
26	Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 669-679.	2.5	34
27	Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes, 2018, 67, 1428-1440.	0.6	32
28	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care, 2018, 41, 2404-2413.	8.6	32
29	Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. Hepatology Communications, 2020, 4, 1041-1055.	4.3	32
30	Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank. Gastroenterology, 2021, 160, 455-458.e5.	1.3	31
31	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2018, 103, 712-721.	4.7	30
32	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Frontiers in Pharmacology, 2016, 7, 135.	3.5	28
33	PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes, 2020, 69, 771-783.	0.6	28
34	Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. Biomolecules, 2020, 10, 551.	4.0	27
35	Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation. Chromosome Research, 2015, 23, 681-708.	2.2	26
36	The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback. Translational Psychiatry, 2017, 7, e1193-e1193.	4.8	25

#	Article	IF	Citations
37	Lymphoblastoid Cell Lines Models of Drug Response: Successes and Lessons from this Pharmacogenomic Model. Current Molecular Medicine, 2014, 14, 833-840.	1.3	22
38	A Genetic Response Score for Hydrochlorothiazide Use. Hypertension, 2016, 68, 621-629.	2.7	21
39	EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. Clinica Chimica Acta, 2017, 471, 216-221.	1.1	21
40	Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. Journal of the American Heart Association, 2018, 7, .	3.7	19
41	Embracing Integrative Multiomics Approaches. International Journal of Genomics, 2016, 2016, 1-5.	1.6	18
42	Diagnostic and Prognostic Significance of Complement in Patients With Alcoholâ€Associated Hepatitis. Hepatology, 2021, 73, 983-997.	7.3	17
43	Alcohol Consumption Is Associated with Poor Prognosis in Obese Patients with COVID-19: A Mendelian Randomization Study Using UK Biobank. Nutrients, 2021, 13, 1592.	4.1	16
44	Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. Oncotarget, 2018, 9, 12164-12173.	1.8	16
45	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. Scientific Data, 2019, 6, 212.	5.3	15
46	Macrophageâ€derived MLKL in alcoholâ€associated liver disease: Regulation of phagocytosis. Hepatology, 2023, 77, 902-919.	7.3	15
47	Salivary metabolites are promising nonâ€invasive biomarkers of hepatocellular carcinoma and chronic liver disease. Liver Cancer International, 2021, 2, 33-44.	1.3	14
48	Predictive Value of Hepatic Venous Pressure Gradient for Graft Hemodynamics in Living Donor Liver Transplantation. Liver Transplantation, 2019, 25, 1034-1042.	2.4	13
49	A genome-wide study of lipid response to fenofibrate in Caucasians. Pharmacogenetics and Genomics, 2016, 26, 324-333.	1.5	12
50	Identifying individual risk rare variants using protein structure guided local tests (POINT). PLoS Computational Biology, 2019, 15, e1006722.	3.2	11
51	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. PeerJ, 2017, 5, e3187.	2.0	11
52	Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma: a pilot study. PeerJ, 2022, 10, e12715.	2.0	11
53	Cheminformatics approach to exploring and modeling trait-associated metabolite profiles. Journal of Cheminformatics, 2019, 11, 43.	6.1	10
54	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. Diabetes Care, 2021, 44, 1410-1418.	8.6	10

#	Article	IF	Citations
55	Assessment of Adverse Events and Their Ability to Discriminate Response to Antiâ€“PD-1/PD-L1 Antibody Immunotherapy. Journal of Clinical Oncology, 2020, 38, 103-104.	1.6	9
56	Metagenomics and chemotherapyâ€induced nausea: A roadmap for future research. Cancer, 2022, 128, 461-470.	4.1	9
57	Associations of weight loss with obesityâ€related comorbidities in a large integrated health system. Diabetes, Obesity and Metabolism, 2021, 23, 2804-2813.	4.4	7
58	A Bioinformatics Crash Course for Interpreting Genomics Data. Chest, 2020, 158, S113-S123.	0.8	6
59	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genomeâ€Wide Interaction Metaâ€Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	4.7	6
60	Comprehensive genomic characterization of five canine lymphoid tumor cell lines. BMC Veterinary Research, 2016, 12, 207.	1.9	5
61	Naturally occuring canine cancers: powerful models for stimulating pharmacogenomic advancement in human medicine. Pharmacogenomics, 2013, 14, 1929-1931.	1.3	4
62	Assessment of potential miRNA biomarkers of VERO-cell tumorigenicity in a new line (AGMK1-9T7) of African green monkey kidney cells. Vaccine, 2017, 35, 5503-5509.	3.8	4
63	PGxClean: a quality control GUI for the Affymetrix DMET chip and other candidate gene studies with non-biallelic alleles. BioData Mining, 2014, 7, .	4.0	3
64	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. Frontiers in Genetics, 2016, 7, 138.	2.3	2
65	Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS). Blood, 2020, 136, 42-43.	1.4	2
66	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. Oncotarget, 2017, 8, 115114-115127.	1.8	1
67	Response to "Accurate Risk-Based Chemical Screening * Relies on Robust Exposure Estimates". Toxicological Sciences, 2012, 128, 297-299.	3.1	0